ReviewMolecular therapy. Nucleic acids2025
The impact of ncRNAs on type 2 diabetes: A comprehensive review covering molecular mechanisms to clinical applications.
Review in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current insights into long non-coding RNAs role for insulin resistance emerging in type 2 diabetes mellitus and its complications.Toxicology reports · 2026Review
- Long non-coding RNAs in the crosstalk between diabetes and colorectal cancer: molecular mechanisms and endocrine pathways.Frontiers in molecular biosciences · 2026Review
- The interplay between exosomal miRNAs and cytokine networks in metabolic diseases.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes (T2D) is a complex metabolic disorder with rising global prevalence. This review examines the diverse roles of non-coding RNAs (ncRNAs) in T2D, focusing on their involvement in key biological processes such as insulin signaling, glucose metabolism, oxidative stress, and inflammation. We explore how ncRNAs interact with known T2D risk genes and contribute to epigenetic regulation associated with disease progression. Particular attention is given to the emerging potential of ncRNAs as biomarkers for early diagnosis and as targets for personalized therapeutic strategies. We also discuss current advances in modulating ncRNA expression, including findings from experimental models and clinical trials published between 1998 and 2025. Finally, the review considers how lifestyle factors and common comorbidities influence ncRNA expression, highlighting their wider implications in the context of T2D. Overall, the findings underscore the growing importance of ncRNAs in understanding, diagnosing, and treating T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.